Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Three clinical trials seeking treatments for a neurological disorder known as Tardive Dyskinesia are currently seeking volunteers. The studies – Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia, Safety and Efficacy of Avastrem (Pryidoxal 5’ –Phosphate) in the Treatment of Tardive Dyskinesia, and Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia – are supported by ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

Tardive Dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs generally prescribed for psychiatric disorders, and some gastrointestinal disorders, such as metoclopramide, commonly known by the brand name Reglan. The condition causes repetitive, involuntary movements that may include grimacing; tongue protrusion; lip smacking, puckering and pursing; and rapid eye blinking. Rapid movements of the fingers, arms, legs and trunk may also occur.

There is no standard treatment for Tardive Dyskinesia. The first step is to stop or minimize the medication that is causing the condition. Symptoms of Tardive Dyskinesia may linger long after discontinuation of the drugs, however with some careful management, some symptoms may improve and/or disappear over time.

If you or a loved one has been injured by neuroleptic drugs like metoclopramide or Reglan, you may have a claim against the manufacturer and may want to seek legal consel.

Related posts:

• Treatments available for drug-induced Tardive Dyskinesia
• Participants needed for clinical trial on new GERD treatment
• Woman with Tardive Dyskinesia sues makers of Reglan
• Tardive dyskinesia in Huntington disease patients on Reglan
• Family asks, ‘Is this Tardive Dyskinesia?’

This entry was posted on Saturday, June 27th, 2009 at 12:02 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.